Index
Law/US Regulatory Framework/FDA

FDA & Drug Approval

The FDA does not directly regulate laboratory animal welfare — that is USDA's role. But the FDA's drug approval requirements have historically been the primary driver of animal testing demand. For decades, FDA regulations effectively mandated animal studies — including dog studies — before human clinical trials could begin. The FDA Modernization Act 2.0 (2022) removed that mandate. The FDA Modernization Act 3.0 (2025) went further. In April 2025, the FDA announced animal testing would become “the exception rather than the norm” within 3–5 years.

1938
original mandate
Federal Food, Drug, & Cosmetic Act
2022
mandate removed
FDA Modernization Act 2.0
3–5 yrs
FDA phase-out timeline
announced April 2025
Key Finding
The FDA is not the enforcer — it is the demand driver. Changing FDA requirements changes the economics of animal testing. When the FDA required dog studies, companies bought dogs. When alternatives become acceptable, the financial incentive to use dogs disappears.

FDA Modernization Act 2.0 & 3.0

The two-species rule, why change is slow, and the future of alternatives

Detailed breakdown of the legislation that ended the 84-year animal testing mandate, what it actually changed, and what it left untouched.

The Demand Curve

1938
Federal Food, Drug, & Cosmetic Act mandates animal safety testing before human use
1962
Kefauver-Harris Amendment strengthens pre-market testing requirements after thalidomide
2022
FDA Modernization Act 2.0 removes the statutory animal testing mandate
2025
FDA Modernization Act 3.0 directs FDA to develop formal alternative-method guidance
2025
FDA announces phase-out plan: animal testing to become "the exception" within 3–5 years
Why This Matters
If the FDA follows through on its 2025 announcement, demand for laboratory beagles could decline dramatically within a decade. The breeders know this — which is why the industry is consolidating, not expanding.